Navigation Links
Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
Date:5/21/2008

Active cellular immunotherapy holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to, risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks related to our limited operating history, risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials will not support approval, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the FDA will not approve a product for which a biologics license has been applied, the risk that the results of a clinical trial may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials or commercialization of products, our dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
5. Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association
6. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
7. Napo Presents at ISPOR Meeting in Toronto
8. Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session
9. Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
10. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
11. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... , March 5, 2015 BioLineRx (NASDAQ: ... biopharmaceutical company dedicated to identifying, in-licensing and developing ... commenced an underwritten public offering of American Depositary ... Ordinary Shares. All of the ADSs in the ... JMP Securities is acting as sole ...
(Date:3/5/2015)... WuXi PharmaTech (Cayman) Inc. (NYSE: WX ), ... serving the pharmaceutical, biotechnology, and medical device industries, with ... its financial results for the fourth quarter and full ... , Net Revenues Increased 21.3% Year Over Year to ... 17.7% Year Over Year to $140.5 Million , ...
(Date:3/5/2015)... -- IRIDEX Corporation (Nasdaq: IRIX ) today reported financial ... 2015.  , Revenues were $11.8 million in the ... up 11% from $10.6 million in the 2013 fourth quarter. ... 12% from $38.3 million in 2013. , Gross margin ... in the fourth quarter of the prior year. , ...
Breaking Medicine Technology:BioLineRx Announces Underwritten Public Offering of its American Depositary Shares 2BioLineRx Announces Underwritten Public Offering of its American Depositary Shares 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 2WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 4WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 6WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 7WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 8WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 9WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 10WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 11WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 12WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 13WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 14WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 15WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 16WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 17WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 18WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 19WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 20WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 21WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 22IRIDEX Reports 2014 Fourth Quarter, Year-End Results 2IRIDEX Reports 2014 Fourth Quarter, Year-End Results 3IRIDEX Reports 2014 Fourth Quarter, Year-End Results 4IRIDEX Reports 2014 Fourth Quarter, Year-End Results 5IRIDEX Reports 2014 Fourth Quarter, Year-End Results 6IRIDEX Reports 2014 Fourth Quarter, Year-End Results 7IRIDEX Reports 2014 Fourth Quarter, Year-End Results 8
(Date:3/6/2015)... 06, 2015 In a new study conducted ... patients reported that shoulder pain was their first mesothelioma symptom. ... website. Click here to read it now. , ... medical records of 49 mesothelioma patients between 2006 ... it was shoulder pain that first prompted them to see ...
(Date:3/6/2015)... 06, 2015 FCPX developers have ... Film Studios. , “Pro3rd Hue is a lower 3rd pack ... of Pixel Film Studios. “Blurring the line between professional and ... Hue is a set of 30 customizable lower third presets ... Pro3rd Hue, FCPX users can complement any design with a ...
(Date:3/6/2015)... 06, 2015 Fluid Running® Owner, Jennifer ... developed the Fluid Running® method 3 years ... Chicago marathon. She hit upon the trifecta of combining ... and a maximum-resistance, deep water running technique. She not ... deep water running workout that made the experience both ...
(Date:3/5/2015)... From Oct. 5-10, Mumbai, India will serve as host ... dates include the following activities:, October ... October 6: Conference Day 1, ending with a Fashion Show ... ending with Local Entertainment and Dinner , October ... Meetings , October 9-10: Textiles in India Tour ...
(Date:3/5/2015)... CA (PRWEB) March 05, 2015 ... of formaldehyde in low-cost laminate flooring products, ... leading manufacturer of eco-friendly building materials made primarily ... safety by testing all their flooring products for ... detection laboratory Benchmark International (BMH). Results ...
Breaking Medicine News(10 mins):Health News:New Report Reveals Shoulder Pain Could Signal Early Mesothelioma, According to Surviving Mesothelioma 2Health News:A New Plugin Entitled Pro3rd Hue was Released Today from Pixel Film Studios Exclusively for FCPX 2Health News:Fluid Running®, the Revolutionary, No-Impact Running Workout, Expands Nationally with New Training Workshop 2Health News:Fluid Running®, the Revolutionary, No-Impact Running Workout, Expands Nationally with New Training Workshop 3Health News:Textile Exchange Announces the 2015 Textile Sustainability Conference Dates 2Health News:With Homeowners Concerned About Formaldehyde, Cali Bamboo Puts Safety Above Bottom Line 2
... to a recent,study(1), more than 6.1 million Americans ... plans, a 35 percent increase since,last year. Consumers ... accounts (FSAs) to cut costs associated with health ... nationwide, is making it easier for shoppers enrolled ...
... MT. LAUREL, N.J., June 18 After 25 years, ... Association (DNA) is,on the brink of a new era. ... thousands of non-members alike can read the latest news,and ... brand-new,publication will be available, in its entirety, online, offering ...
... Martin promoted to lead College Living Experience, ... (ESA) today announced Stephanie Martin has been appointed ... (CLE), an ESA,program that helps students with autism ... be responsible for all operations, clinical, behavioral and,curricular ...
... /PRNewswire-FirstCall/ - SXC Health Solutions Corp.,("SXC" or the ... leading provider of,pharmacy benefits management services, announces that ... the Jefferies 2nd Annual Healthcare,Conference in New York ... 24, 2008 at 11:45 am ET., SXC,s ...
... Florida department of urology officials signed an agreement ... CureVac to test an experimental therapy for advanced ... traditional treatment. , CureVac which specializes in ... that transfers genetic information from nuclear DNA to ...
... 150,000 Identities, ANDOVER, Mass., June 18 ... seven healthcare organizations have selected,Sentillion,s proVision solution to ... challenges of manual user account,management, including:, ... Baptist Health System (Birmingham, AL) -- Hawaii ...
Cached Medicine News:Health News:CVS/pharmacy Makes It Easier for Consumers to Save Money and Track Spending with Health Savings and Flexible Spending Accounts 2Health News:CVS/pharmacy Makes It Easier for Consumers to Save Money and Track Spending with Health Savings and Flexible Spending Accounts 3Health News:CVS/pharmacy Makes It Easier for Consumers to Save Money and Track Spending with Health Savings and Flexible Spending Accounts 4Health News:Dermatology Nurses' Association Teams with International Publisher to Launch its Own Journal 2Health News:Dermatology Nurses' Association Teams with International Publisher to Launch its Own Journal 3Health News:Educational Services of America Names a New Senior VP of Operations 2Health News:UF scientists to work with German firm in prostate cancer treatment research 2Health News:Leading Healthcare Organizations Overwhelmingly Select Sentillion for User Provisioning 2Health News:Leading Healthcare Organizations Overwhelmingly Select Sentillion for User Provisioning 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: